This HTML5 document contains 44 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n16https://global.dbpedia.org/id/
yagohttp://dbpedia.org/class/yago/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n7http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
freebasehttp://rdf.freebase.com/ns/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
provhttp://www.w3.org/ns/prov#
dbchttp://dbpedia.org/resource/Category:
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
goldhttp://purl.org/linguistics/gold/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:MDX-1097
rdf:type
yago:Activity100407535 dbo:ChemicalSubstance yago:PsychologicalFeature100023100 yago:YagoPermanentlyLocatedEntity yago:Procedure101023820 yago:Event100029378 n7:ChemicalObject wikidata:Q8386 dbo:MonoclonalAntibody owl:Thing yago:Abstraction100002137 dbo:Drug yago:MedicalProcedure101024392 yago:Act100030358 yago:WikicatMedicalProcedures
rdfs:label
MDX-1097
rdfs:comment
MDX-1097 (also called IST-1097 or KappaMab) is a monoclonal antibody therapy being assessed in Phase IIb clinical trials as a treatment for multiple myeloma, a type of white blood cell cancer. It is a chimeric version of the mouse monoclonal antibody K-1-21. MDX-1097 targets kappa free immunoglobulin light chains which are found on the surface of some kappa light chain-restricted myeloma cells. MDX-1097 was originally developed by scientists at Immune System Therapeutics Ltd. In 2015, Haemalogix Pty Ltd acquired the rights to MDX-1097 and are now taking it through late stage clinical testing.
dcterms:subject
dbc:Monoclonal_antibodies_for_tumors
dbo:wikiPageID
42634358
dbo:wikiPageRevisionID
1032475924
dbo:wikiPageWikiLink
dbr:Multiple_myeloma dbc:Monoclonal_antibodies_for_tumors dbr:Monoclonal_antibody dbr:Chimeric_antibody dbr:Monoclonal_antibody_therapy dbr:Immunoglobulin_light_chain
owl:sameAs
yago-res:MDX-1097 n16:mxL7 freebase:m.010rgd3y wikidata:Q18351048
dbp:wikiPageUsesTemplate
dbt:Orphan dbt:Antineoplastic-drug-stub dbt:Monoclonal-antibody-stub dbt:Infobox_drug dbt:Reflist
dbp:casNumber
1793022
dbp:synonyms
IST-1097; KappaMab
dbp:type
mab
dbo:abstract
MDX-1097 (also called IST-1097 or KappaMab) is a monoclonal antibody therapy being assessed in Phase IIb clinical trials as a treatment for multiple myeloma, a type of white blood cell cancer. It is a chimeric version of the mouse monoclonal antibody K-1-21. MDX-1097 targets kappa free immunoglobulin light chains which are found on the surface of some kappa light chain-restricted myeloma cells. MDX-1097 was originally developed by scientists at Immune System Therapeutics Ltd. In 2015, Haemalogix Pty Ltd acquired the rights to MDX-1097 and are now taking it through late stage clinical testing.
gold:hypernym
dbr:Therapy
prov:wasDerivedFrom
wikipedia-en:MDX-1097?oldid=1032475924&ns=0
dbo:wikiPageLength
4263
dbo:casNumber
1793022-75-9
foaf:isPrimaryTopicOf
wikipedia-en:MDX-1097